sponsored
PatientsVille.com Logo

PatientsVille

Salicylic Medical Research Studies

Up-to-date List of Salicylic Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Salicylic Medical Research Studies

Rank Status Study
1 Recruiting Effectiveness of Night Administration of Low Dose Aspirin in Hypertensive Patients
Condition: Hypertension
Interventions: Drug: Acetylsalicylic acid 100 mg in the evening and placebo in the morning;   Drug: Acetylsalicylic acid at day time;   Drug: Placebo
Outcome Measures: Mean SBP and DBP measured with Ambulatory Blood Pressure Monitoring (ABPM) over a 24 hour period;   Mean of day/night SBP and DBP ratios measured with Ambulatory Blood Pressure monitoring Monitoring;   The mean of heart rate (HR) and the mean of pulse pressure (PP);   Percentage of adverse events related to ASA evening administration versus day administration
2 Unknown  Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder
Conditions: Schizophrenia;   Schizoaffective Disorder
Interventions: Drug: minocycline;   Drug: pramipexole;   Drug: Acetylsalicylic acid;   Drug: placebo
Outcome Measures: Positive and Negative Syndrome Scale (PANSS)total score;   Positive and Negative Syndrome Scale (PANSS);   Clinical Global Impression Scale-Severity (CGI-S);   Clinical Global Impression Scale-Severity(CGI-S);   Clinical Global Impression Scale- Improvement (CGI-I);   Brief Assessment of Cognition in Schizophrenia (BACS)
3 Not yet recruiting Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers
Conditions: Lung Cancer;   Tobacco Use Disorder
Interventions: Drug: Acetylsalicylic acid;   Other: placebo;   Other: laboratory biomarker analysis
Outcome Measures: Changes in a smoking-related gene expression signature of nasal epithelium;   Persistence of the change in the smoking-related gene expression signature of nasal epithelium one week off agent intervention;   Change in urine PGE-M expression;   Change in urine LTE(4) expression;   Lung cancer- related gene expression signatures in the nasal epithelium;   Persistence of the change in the lung cancer-related gene expression signatures of the nasal epithelium one week off agent intervention;   Frequency of adverse events (AEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;   Smoking-related gene expression signature;   Whole-genome gene expression
4 Unknown  Efficacy and Safety Clinical Trial of the Combination of Acetylsalicylic Acid, Sodium Bicarbonate and Citric Acid, Produced by Geolab Pharmaceutical Industries Ltd., Compared to Acetylsalicylic Acid (Aspirin ® - Bayer) in Patients With Episodic Tension-type Headache.
Condition: Treatment of Episodic Tension Headache
Interventions: Drug: Association: Acetylsalicylic acid (500mg), sodium bicarbonate (1625) and citric acid (965);   Drug: Aspirin - Bayer
Outcome Measures: The primary efficacy endpoint is the rate of sustained response (percentage of subjects who have no pain) two hours after the drug administration.;   • Reduction of associated symptoms (photophobia, phonophobia, nausea, vomiting); • Symptoms stomach before and after treatment • Change in gastric pH after administration; • Incidence of administration of rescue medications; • Change in pain
5 Recruiting Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
Conditions: Pre-Eclampsia;   Fetal Growth Retardation;   Prematurity of Fetus;   Placental Insufficiency
Interventions: Drug: Acetylsalicylic acid (ASA) 160 mg;   Drug: Acetylsalicylic acid (ASA) 80 mg
Outcome Measures: Placental function;   Rates of pregnancy complications related to placental insufficiency (preeclampsia, IUGR, premature birth)
6 Recruiting Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
Condition: Adenomatous Polyp
Interventions: Drug: eflornithine;   Drug: Acetylsalicylic acid;   Other: placebo;   Other: laboratory biomarker analysis;   Other: telephone-based intervention
Outcome Measures: Adenoma recurrence rate for the treatment arm relative to placebo;   Comparison of the percent change in ACF number across the 2 treatment arms;   Characterization of ACF;   Safety, tolerability, and adverse events of study treatment;   ACF characteristics vs adenoma recurrence rate;   Gene expression analysis;   Effect of the study drugs and placebo with respect to biomarkers
7 Not yet recruiting Challenge Test for Acetylsalicylic Acid Hypersensitivity
Conditions: Asthma Aspirin-sensitive;   ASA Intolerant Asthma;   Asthma, Aspirin-Induced;   Asthma, Nasal Polyps, and Aspirin Intolerance
Interventions: Drug: Acetylsalicylate;   Drug: Isotonic NaCl
Outcome Measures: Inspiratory nasal flow measured by Rhinomanometry;   Expiratory nasal flow measured by Rhinomanometry;   Pulmonary forced expiratory volume in 1 second (FEV1);   Conjunctival symptoms;   Nasal symptoms;   Bronchial and laryngeal symptoms
8 Recruiting Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Recurrent Non-small Cell Lung Cancer;   Stage IA Non-small Cell Lung Cancer;   Stage IB Non-small Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: Acetylsalicylic acid;   Other: laboratory biomarker analysis
Outcome Measures: Change in PGE2 biosynthesis from baseline and at 14 days after discontinuation of a 7-day course of 325 mg ASA per day;   Change in PGE-M levels from baseline and daily for 7 days after discontinuation of a 7-day course of 325 mg ASA per day
9 Not yet recruiting Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of Action
Condition: Colorectal Cancer
Interventions: Drug: Acetylsalicylic acid;   Procedure: Screening colonoscopy
Outcome Measures: Assessment of the degree of COX-1 acetylation by ASA administered for 1 week.;   Changes from baseline in different biomarkers.;   Changes from baseline in eicosanoid generation in vivo by measuring urinary metabolites derived from COXs.;   Changes in baseline platelet COX-1;   Change from baseline in plasma proteins of markers of angiogenesis.;   Assessment of ASA plasma levels.;   Changes from baseline of proteomic profile of selected angiogenesis factors, ie VEGF, FGF2, TGFbeta, EGF, PDGF, MMP, angiogenin, and angiogenesis inhibitors, ie endostatin, PF4, thrombospondin 1, alpha-macroglobulin, PAI 1 and angiostatin.;   Change from baseline in eicosanoid biosynthesis and protein expression of markers of growth and progression of colorectal cancer (such as COX-2, NF-Kb and PI3K/Akt/mTOR pathway).
10 Not yet recruiting Inducing Immune Quiescence to Prevent HIV Infection in Women
Condition: HIV
Interventions: Drug: Acetylsalicylic Acid (ASA);   Drug: Hydroxychloroquine (HCQ)
Outcome Measures: Change in systemic immune activation from baseline observed by a decrease of HLA-DR and CD69 expression on CD4 T cells;   Change in number of HIV target cells from baseline by reduction of CCR5+CD4+ T cell population at the female genital tract.
11 Unknown  The Antiaggregation Monitoring (TAM) Registry
Condition: Aspirin Causing Adverse Effects in Therapeutic Use
Intervention: Other: Measurement of platelet anti-aggregation
Outcome Measure: Whole blood impedance platelet aggregometry to assess Acetylsalicylic acid resistance rates
12 Recruiting Anticoagulation in Stent Intervention
Conditions: Atrial Fibrillation;   Stroke
Interventions: Drug: Acetylsalicylic Acid + clopidogrel + acenocoumarol;   Drug: Acetylsalicylic Acid + clopidogrel
Outcome Measures: A composite of stroke, myocardial infarction, systemic thromboembolism, stent thrombosis and death;   Incidence of major and minor bleeding;   Adverse events
13 Recruiting BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)
Condition: Acute Coronary Syndrome
Intervention: Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781)
Outcome Measures: The primary efficacy variable will be the TXB2 (Thromboxane B2) concentration at 5 minutes after study drug administration.;   TXB2 (Thromboxane B2) values at 20 minutes;   Platelet aggregation inhibition;   Serum prostacyclin levels;   Incidence of post randomization deaths from all causes, cardiovascular deaths, myocardial re/infarctions and ischemic strokes;   Safety laboratory examinations, vital signs, physical examination, ECG, adverse events collection;   Incidence of all post randomization strokes of unknown etiology;   Incidence of all post randomization bleedings assessed according to the TIMI (thrombolysis in myocardial infarction) classification including hemorrhagic stroke;   Hospital mortality during the hospitalization for ACS (Acute Coronary Syndrome)
14 Recruiting [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
Conditions: Acute Ischaemic Stroke;   Transient Ischaemic Attack.
Interventions: Drug: ticagrelor;   Drug: Acetylsalicylic acid (ASA)
Outcome Measures: Composite of stroke, MI and death.;   Prevention of subsequent ischaemic stroke.;   Net clinical outcome.;   Time to discontinuation of study medication due to any bleeding event.;   Composite of ischaemic stroke, MI and CV death.
15 Recruiting Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD
Condition: Cervical Artery Dissection
Interventions: Drug: Acetylsalicylic acid;   Drug: vitamin K-antagonist
Outcome Measures: Cerebrovascular Ischemia, major Hemorrhagic events or Death (CIHD);   New ischemic strokes; new acute DWI lesions; any major extracranial bleeds; any symptomatic intracranial bleeds; any asymptomatic bleeds; any death; any increase in vessel wall hematoma; mRS 0-2; mRS 0-1; any transient ischemic attack (TIA)
16 Recruiting Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers
Condition: Colorectal Cancer
Interventions: Other: placebo;   Drug: Acetylsalicylic acid
Outcome Measures: Disease-free survival;   Overall survival
17 Recruiting ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery
Conditions: Graft Patency;   Coronary Artery Bypass Grafting Surgery;   Hypercoagulability;   Thrombosis
Interventions: Drug: Clopidogrel+Acetylsalicylic acid;   Drug: Acetylsalicylic acid
Outcome Measures: Graft patency at 3 months;   Rate of other thromboembolic events( e.g. myocardial infarction,stroke, pulmonary embolus etc.)and cardiovascular death;   Assessing coagulation profile pre- and postoperatively, including aspirin and clopidogrel resistance
18 Recruiting Triple vs. Dual Therapy
Conditions: Atrial Fibrillation;   Acute Coronary Syndrome
Interventions: Drug: Ticagrelor + Apixaban + ASA;   Drug: Ticagrelor + Apixaban
Outcome Measures: β-thromboglobulin (β-TG);   Prothrombin fragment F1+2 (F1+2);   Thrombin-Anti-Thrombin (TAT);   D-dimer;   P-selectin
19 Recruiting GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation
Condition: Coronary Artery Disease (CAD)
Interventions: Drug: Ticagrelor;   Drug: Acetylsalicylic Acid;   Drug: Clopidogrel
Outcome Measures: Composite of all-cause mortality or non-fatal new Q-wave MI;   Bleeding
20 Not yet recruiting The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin
Condition: Gastrointestinal Hemorrhage
Interventions: Drug: Aspirin (ASA);   Drug: Placebo
Outcome Measures: Clinically significant bleeding after colorectal polypectomy;   Proportion of composite cardiovascular events, ending unplanned hospitalization in both groups aspirin and placebo;   Proportion of clinically significant delayed bleeding in both groups

These studies may lead to new treatments and are adding insight into Salicylic etiology and treatment.

A major focus of Salicylic research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Salicylic